I-Mab Presents Promising Phase 1b Givastomig Combination Data for Gastric Cancers at ESMO GI 2025

I-Mab (NASDAQ:IMAB) is one of the best-performing NASDAQ stocks according to analysts. On July 2, I-Mab announced the presentation of positive Phase 1b combination data for givastomig at the European Society for Medical Oncology Gastrointestinal Cancers Congress 2025 (ESMO GI 2025) in Barcelona.

Givastomig, which is a bispecific antibody that targets Claudin 18.2 (CLDN18.2) and 4-1BB, was evaluated in combination with nivolumab (an anti-PD-1 checkpoint inhibitor) and mFOLFOX6 (a chemotherapy regimen including leucovorin calcium, fluorouracil, and oxaliplatin) as a first-line (1L) therapy for patients with CLDN18.2-positive gastric cancers.

I-Mab Presents Promising Phase 1b Givastomig Combination Data for Gastric Cancers at ESMO GI 2025

A scientist in a laboratory carefully handling a long-acting human growth hormone experiment.

The primary endpoint of the study was safety, and givastomig showed favorable overall tolerability. There were no Grade 3 or greater events for nausea and vomiting, and only one Grade 3 treatment-related adverse event/TRAE for increased liver enzymes.

I-Mab (NASDAQ:IMAB) is a biotech company that develops immuno-oncology agents for the treatment of cancer in the US.

While we acknowledge the potential of IMAB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IMAB and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.